Korebrits C, Yu D H, Ramirez M M, Marinoni E, Bocking A D, Challis J R
Department of Obstetrics and Gynaecology, University of Western Ontario, St Joseph's Health Centre, London, Canada.
Br J Obstet Gynaecol. 1998 May;105(5):556-61. doi: 10.1111/j.1471-0528.1998.tb10158.x.
This study was designed to determine whether maternal corticotrophin-releasing hormone (CRH) concentrations are altered after maternal betamethasone administration for fetal lung maturity in women with threatened preterm labour and whether these effects are dependent on gestational age.
Our study included 49 women with threatened preterm labour who received prenatal betamethasone for fetal lung maturity between 24 and 31 weeks of gestational age and 11 women who did not. Maternal blood was taken before and after glucocorticoid administration or at 24 hours after initial sampling. Plasma CRH, adrenocorticotrophin (ACTH) and cortisol concentrations were determined by radioimmunoassays. The women were stratified into 24-25 weeks, 26-27 weeks, 28-29 weeks, and 30-31 weeks completed gestation.
At each gestational age, maternal cortisol concentrations decreased by approximately 85% after glucocorticoid administration. Overall mean cortisol values fell from 580.0 (SD, 351.8) to 89.7 (96.6) nmol/L (n = 40, P < 0.001). Overall mean ACTH values decreased from 9.9 (4.7) to 5.0 (3.4) pmol/L (n = 43, P < 0.001), and the approximate 50% decrease was similar at each gestational age. In marked contrast, overall mean CRH values increased from 58.0 (37.0) to 87.8 (68.6) pmol/L (n = 49, P < 0.001) after betamethasone administration. There was no change in maternal cortisol, ACTH or CRH values over 24 hours in women who did not receive betamethasone.
We conclude that maternal betamethasone administration increases maternal plasma CRH values between 24 and 31 completed weeks of gestation.
本研究旨在确定对于有早产风险的孕妇,给予倍他米松促进胎儿肺成熟后,母体促肾上腺皮质激素释放激素(CRH)浓度是否会发生改变,以及这些影响是否取决于孕周。
我们的研究纳入了49名有早产风险且在孕24至31周期间接受产前倍他米松以促进胎儿肺成熟的孕妇,以及11名未接受该治疗的孕妇。在给予糖皮质激素之前和之后或首次采样后24小时采集母体血液。通过放射免疫分析法测定血浆CRH、促肾上腺皮质激素(ACTH)和皮质醇浓度。将这些孕妇按完成孕周分为24 - 25周、26 - 27周、28 - 29周和30 - 31周组。
在每个孕周,给予糖皮质激素后母体皮质醇浓度下降约85%。总体平均皮质醇值从580.0(标准差,351.8)降至89.7(96.6)nmol/L(n = 40,P < 0.001)。总体平均ACTH值从9.9(4.7)降至5.0(3.4)pmol/L(n = 43,P < 0.001),且在每个孕周约50%的下降幅度相似。与之形成显著对比的是,给予倍他米松后总体平均CRH值从58.0(37.0)升至87.8(68.6)pmol/L(n = 49,P < 0.001)。未接受倍他米松的孕妇在24小时内母体皮质醇、ACTH或CRH值无变化。
我们得出结论,在孕24至31周期间给予母体倍他米松会增加母体血浆CRH值。